This video reviews the first-line treatment of metastatic renal cell carcinoma, including for those patients who are ineligible for interleukin-2.
In this video, Neeraj Agarwal, MD, of the University of Utah Huntsman Cancer Institute, reviews the first-line treatment of metastatic renal cell carcinoma, including for those patients who are ineligible for treatment with high-dose interleukin-2.
Agarwal spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
